Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

In this conversation, Kremens discussed the common use of antiemetics in Parkinson disease, the real-world data surrounding these agents, and whether there are certain clinical advantages to apomorphine hydrochloride injection.

Use of Antiemetics in Parkinson Care

Articles

A recent study showed the relationship between genes associated with lysosomal function and environmental exposure to pesticides in Parkinson disease.

Lysosomal Function Gene Variants of Parkinson Disease Enriched When Exposed to Pesticides

Daniel Kremens, MD, JD, provided commentary on a number of various amantadine formulations for Parkinson disease, and how timing of dosing impacts efficacy. 

Optimizing Dosing and Treatment Selection of Amantadine

The associate professor of chemistry at Vanderbilt University talked about research surrounding racial and ethnic disparities in Alzheimer disease incidence. [WATCH TIME: 5 minutes]

Insights on Addressing Disparities in Alzheimer Disease Research: Renã A. S. Robinson, PhD

Associate professor of chemistry at Vanderbilt University and the inaugural Dorothy J. Wingfield Phillips Chancellor’s Faculty Fellow.

The professor of neurology at the NYU Grossman School of Medicine provided commentary on a study that demonstrated the benefits of using tDCS along with sleep language training to promote naming in primary progressive aphasia. [WATCH TIME: 5 minutes]

Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Leigh Charvet, PhD

, has been with the team since October 2019. Follow him on Twitter 

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center provided commentary on the need to properly diagnose Lennox-Gastaut syndrome and the negative downstream impacts of misdiagnosis or underdiagnosing patients.

NeuroVoices: Scott Perry, MD, on the Intricacies and Value of Diagnosing Lennox-Gastaut Syndrome

Lauren Seidman, a second-year medical student at NYU Langone’s Grossman School of Medicine, provided perspective on a poster at AAN 2024 highlighting the use of binocular visual function testing in Alzheimer disease.

Understanding the Clinical Utility of Low-Contrast Letter Acuity and RAN Tasks in Alzheimer Disease

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

New Directions in the Treatment Myasthenia Gravis

A. Gordon Smith, MD, FAAN, offers perspective on the challenges of diagnosis, new developments in therapeutics, and the need for interdisciplinary collaboration for optimal patient care.

A. Gordon Smith, MD, FAAN, reviews prevalence and subtypes of myasthenia gravis. He also discusses how different antibodies contribute to the pathophysiology of the disease. 

Prevalence and Pathophysiology of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, recounts the challenges of treating patients with myasthenia gravis. He also discusses care disparities and the need for rapid disease modification.

Unmet Needs in the Management of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, discusses the role of acetylcholine esterase inhibitors, immunosuppressive agents, IV immunoglobulin, corticosteroids, as well as newer agents in the treatment of myasthenia gravis.

Standards of Care for Myasthenia Gravis

A. Gordon Smith, MD, FAAN, considers how rituximab and eculizumab fit into the current standard of care for myasthenia gravis.

The Role of Monoclonal Antibodies in the Treatment of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, explores the rationale for targeting the neonatal Fc receptor and the mechanisms for efgartigimod for use in the treatment of myasthenia gravis.

The Fc Receptor and Mechanisms of Efgartigimod

A. Gordon Smith, MD, FAAN, discusses the findings and implications of phase 3 ADAPT trial and open-label extension study evaluating the use of efgartigimod in the treatment of patients with myasthenia gravis.

Clinical Trial Data for Efgartigimod in the Treatment of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, talks about how new agents and emerging data are enabling clinicians to personalize care for patients with myasthenia gravis.

Evolving Approaches to Treatment Selection in the Management of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, discusses how to assess for treatment success and why the patient perspective is so important in deciding whether to change therapies.

Determining Treatment Efficacy in the Treatment of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, describes the landscape of investigational therapies for myasthenia gravis, including plasma cells, CAR-T, antigen-specific tolerance.

Investigational Agents for the Treatment of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, talks about the importance of collaboration and education amid advances in myasthenia gravis treatment, from new formulations and routes of administration to innovative targets.

Collaborating With Primary Care Physicians for the Management of Patients With Myasthenia Gravis

Clinical

Lasso - DMD Peers and Perspectives NSP-21-NRD0157

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Determining Treatment Efficacy in the Treatment of Myasthenia Gravis

EP: 1.Prevalence and Pathophysiology of Myasthenia Gravis

EP: 2.Unmet Needs in the Management of Myasthenia Gravis

EP: 3.Standards of Care for Myasthenia Gravis

EP: 4.The Role of Monoclonal Antibodies in the Treatment of Myasthenia Gravis

EP: 5.The Fc Receptor and Mechanisms of Efgartigimod

EP: 6.Clinical Trial Data for Efgartigimod in the Treatment of Myasthenia Gravis

EP: 7.Evolving Approaches to Treatment Selection in the Management of Myasthenia Gravis

EP: 8.Determining Treatment Efficacy in the Treatment of Myasthenia Gravis

EP: 9.Investigational Agents for the Treatment of Myasthenia Gravis

EP: 10.Collaborating With Primary Care Physicians for the Management of Patients With Myasthenia Gravis